Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Roluperidone - Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation

Drug Profile

Roluperidone - Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation

Alternative Names: CYR-101; MIN-101; MT-210

Latest Information Update: 23 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Minerva Neurosciences
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Fluorobenzenes; Isoindoles; Piperidines; Small molecules
  • Mechanism of Action Alpha-1a adrenergic receptor antagonists; Serotonin 2A receptor antagonists; Sigma-2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Schizophrenia
  • Preclinical Dementia
  • Research Alzheimer's disease; Parkinson's disease; Pervasive child development disorders

Most Recent Events

  • 08 Mar 2023 Minnerva Neurosciences has patent protection for methods of use for roluperidone in Russia, Canada, Anguilla, Bermuda, Cayman Islands, Gibraltar, Jersey, Turks & Caicos Islands, and British Virgin Islands, prior to March 2023
  • 08 Mar 2023 Minnerva Neurosciences has patent protection for novel formulation of roluperidone in Australia, Chile, Colombia, Europe, Israel, Mexico, and Ukraine, prior to March 2023
  • 30 Nov 2022 Minerva Neurosciences provides update from Type A meeting with the US FDA for roluperidone in Schizophrenia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top